Positioning Cabozantinib Across Treatment Strategies in Advanced Renal Cell Carcinoma

In this segment on advanced renal cell carcinoma, Dr. Wulff focuses on the role of cabozantinib across different treatment settings and how clinicians decide between monotherapy and combination approaches in practice. Dr. McGregor and Dr. Geynisman discuss how cabozantinib is utilized both as part of IO-TKI combinations in the first-line setting and as a single agent in patients who are not candidates for immunotherapy or in later lines of treatment. The panel highlights that patient-specific factors such as comorbidities, prior therapy exposure, and tolerance to immunotherapy play a central role in this decision. In patients with contraindications to IO or concerns about immune-related toxicity, cabozantinib monotherapy remains a practical and effective option. Conversely, combination approaches may be preferred in patients who are appropriate for IO and require a more aggressive upfront strategy. The discussion reinforces the flexibility of cabozantinib and its relevance across the treatment continuum in advanced renal cell carcinoma.